Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 7:33 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 217–240 of 362 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Electrocardiogram (ECG) Clear all

Conditions: Atrial Fibrillation, Arrhythmias, Cardiac, Atrial Flutter
Interventions: Ambulatory ECG; Device
Lead sponsor: Apple Inc.; Industry
Eligibility: 22 Years and older
Enrollment: 17 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Stanford, California

Conditions: Locally Advanced Pancreatic Ductal Adenocarcinoma, Metastatic Pancreatic Ductal Adenocarcinoma, Stage II Pancreatic Cancer AJCC v8, Stage III Pancreatic Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8, Unresectable Pancreatic Adenocarcinoma
Interventions: Onvansertib, Gemcitabine, Nab-paclitaxel, Electrocardiography, Magnetic Resonance Imaging, Positron Emission Tomography, Biospecimen Collection, Computed Tomography; Drug · Procedure
Lead sponsor: OHSU Knight Cancer Institute; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: ST Elevated Myocardial Infarction
Interventions: Alivecor Heart Monitor; Device
Lead sponsor: INTEGRIS Baptist Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 1
States / cities: Oklahoma City, Oklahoma

Conditions: High Grade Glioma, Anaplastic Astrocytoma, Anaplastic Oligodendroglioma, Glioblastoma
Interventions: Regadenoson 0.05mg, Regadensoson 0.1mg, Regadensoson 0.2mg, Regadensoson 0.4mg, Regadensoson 0.7mg, Regadensoson 1.0mg, Regadensoson 1.4mg; Drug
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 18 Years to 45 Years
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 2
States / cities: Baltimore, Maryland • Winston-Salem, North Carolina

Conditions: Cystic Fibrosis
Interventions: Wearable device; Device
Lead sponsor: Byteflies; Industry
Eligibility: 18 Years and older
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Chest Pain, Myocardial Infarction, Myocardial Ischemia, Acute Coronary Syndrome
Interventions: Not listed
Lead sponsor: University of Pittsburgh; Other
Eligibility: 18 Years and older
Enrollment: 6,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2023
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Atrial Fibrillation
Interventions: 1-Lead ECG, 12-Lead ECG; Other · Device
Lead sponsor: Apple Inc.; Industry
Eligibility: 22 Years and older
Enrollment: 602 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018
U.S. locations: 5
States / cities: Miami, Florida • Orlando, Florida • The Villages, Florida + 2 more

Conditions: Electroencephalography, Electrocardiography, Respiratory Rate, Surveys and Questionnaires
Interventions: Yoga Nidra; Other
Lead sponsor: National University of Natural Medicine; Other
Eligibility: 18 Years to 45 Years
Enrollment: 22 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Cardiac Catheter Ablation, Atrial Flutter, Cardiac Arrhythmias
Interventions: Data Collection During Atrial Flutter Ablation; Other
Lead sponsor: David B. De Lurgio; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 2
States / cities: Atlanta, Georgia

Conditions: Death, Sudden, Cardiac, Ventricular Fibrillation, Tachycardia, Ventricular
Interventions: Defibrillation of pulseless VT/VF by AECD; Device
Lead sponsor: Foundation for Atlanta Veterans Education and Research, Inc.; Other
Eligibility: 18 Years and older
Enrollment: 192 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 1
States / cities: Decatur, Georgia

Conditions: Autism Spectrum Disorder, Anxiety
Interventions: Lief Smart Patch; Device
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 12 Years to 17 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Lexington, Massachusetts

Conditions: Muscular Dystrophy, Arrhythmia, Sudden Cardiac Death
Interventions: Screening; Other
Lead sponsor: Indiana University; Other
Eligibility: 18 Years and older
Enrollment: 448 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1996 – 2015
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Prolonged QT Interval in EKG and Sudden Death
Interventions: Progesterone, Placebo, Ibutilide; Drug
Lead sponsor: Indiana University; Other
Eligibility: 21 Years to 40 Years · Female only
Enrollment: 19 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2014
U.S. locations: 2
States / cities: Indianapolis, Indiana

Conditions: HIV Infections
Interventions: Eye exam, Oral exam, CT scan, Neuropsychological testing, Electrocardiogram, Echocardiogram; Procedure
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: Not listed
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2006
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Lymphoproliferative Disorders, Autoimmune Lymphoproliferative, Primary T-cell Immunodeficiency Disorders, Immune System Diseases, Common Variable Immunodeficiency
Interventions: e-ATG, Immunosuppression Only Conditioning, Reduced Intensity Conditioning, GVHD Prophylaxis, Allogeneic HSC, Bisulfan, Prednisone, Cyclophosphamide, MMF, Mesna, Tacrolimus, Pentostatin, PFTs, DEXA, Bone Marrow Aspirate & Biopsy, EKG, 2D ECHO; Drug · Procedure · Diagnostic Test
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 4 Years and older
Enrollment: 71 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2030
U.S. locations: 2
States / cities: Bethesda, Maryland • Minneapolis, Minnesota

Conditions: Gastrointestinal Cancer, Pancreatic Cancer, Gastric Cancer, Colon Cancer, Rectal Cancer
Interventions: Cyclophosphamide, Fludarabine, Aldesleukin, anti-Kirsten rat sarcoma virus (KRAS) Glycine(G) to Aspartic Acid(D) substitution at codon 12 peripheral blood lymphocytes (PBL), EKG, CT, MRI, PET, Chest x-ray, Photography; Drug · Biological · Diagnostic Test + 1 more
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 72 Years
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Left Branch Bundle Block, RV - Right Ventricular Abnormality
Interventions: Pacemaker Interrogation and Electrocardiogram (ECG):, Cardiopulmonary Exercise Test (CPET) and Exercise Stress Cardiac Magnetic Resonance (ExeCMR, Continuous pacemaker telemetry (CPT); Other
Lead sponsor: Virginia Commonwealth University; Other
Eligibility: 18 Years and older
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Richmond, Virginia

Conditions: Aphthous Stomatitis, Burning Mouth Syndrome, Lichen Planus, Mouth Disease, Temporomandibular Joint Disorder
Interventions: Electrocardiogram, Biopsies, Diagnostic imaging; Procedure
Lead sponsor: National Institute of Dental and Craniofacial Research (NIDCR); NIH
Eligibility: Not listed
Enrollment: 999 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1997 – 2002
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: COVID-19
Interventions: Bronchoscopies and Bronchoalveolar Lavages (BALs), Chest Tomography (CT), Electrocardiogram (ECG), Pulmonary function tests (PFTs), 6 minute walk test (6MWT); Procedure · Diagnostic Test
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 67 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Healthy
Interventions: Danicopan, Moxifloxacin-matching Placebo, Danicopan-matching placebo, Moxifloxacin; Drug
Lead sponsor: Alexion Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 33 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018
U.S. locations: 1
States / cities: Tempe, Arizona

Conditions: Diabetes, Diabetes Mellitus, Type 2
Interventions: liraglutide, placebo, moxifloxacin, electrocardiogram (ECG); Drug · Procedure
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 64 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006
U.S. locations: 1
States / cities: Fargo, North Dakota

Conditions: Healthy
Interventions: ALXN1840, Placebo, Moxifloxacin; Drug
Lead sponsor: Alexion Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 57 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Recurrent Chronic Lymphocytic Leukemia, Recurrent Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia, Refractory Small Lymphocytic Lymphoma
Interventions: Biospecimen Collection, Bone Marrow Biopsy, Computed Tomography, Electrocardiogram, Ibrutinib, Lenalidomide, Magnetic Resonance Imaging, Rituximab; Procedure · Drug · Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2027
U.S. locations: 2
States / cities: Washington D.C., District of Columbia • Hackensack, New Jersey

Conditions: Cutaneous T-Cell Lymphoma, Mature T-cell Malignancies, Peripheral T-Cell Lymphoma, Relapsed/ Refractory T-cell Malignancies
Interventions: Romidepsin, Lenalidomide, CC-486 (5-azacitidine), Dexamethasone, EKG, Bone Marrow Aspiration/Biopsy, MRI, Lumbar Puncture, TTE; Drug · Diagnostic Test · Procedure
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 1
States / cities: Bethesda, Maryland

Search by objective public record fields.

Evaluation of the Use of Apple Watch Features for Identification of Cardiac Arrhythmias

Onvansertib in Combination With Gemcitabine and Nab-paclitaxel for the Treatment of Patients With Locally-advanced, Unresectable, or Metastatic Pancreatic Ductal Adenocarcinoma

Smartphone Twelve Lead Electrocardiogram Utility In ST Elevation Myocardial Infarction

Determining Dose of Regadenoson Most Likely to Transiently Alter the Integrity of the Blood-Brain Barrier in Patients With High Grade Gliomas

Continuous Cardiorespiratory Monitoring in Cystic Fibrosis

ECG Methods for the Prompt Identification of Coronary Events

Electrocardiogram Clinical Validation Study

A Closer Look at Yoga Nidra: Sleep Lab Analyses

Determination of Catheter Contact by Evaluation of Microelectrode Near-Field Signals

Automatic External Defibrillation Monitoring in Cardiac Arrest

Heart Rate Variability Biofeedback for Anxiety in Autistic Youth

Arrhythmias in Myotonic Muscular Dystrophy

Influence of Progesterone Administration on Drug-Induced QT Interval Lengthening

Effect of Tenofovir DF on Bone Metabolism in Children

Allogeneic Hematopoietic Cell Transplantation for Disorders of T-cell Proliferation and/or Dysregulation

Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12D Variant of Mutated RAS in HLA-A*11:01 Patients

Functional Outcomes in CondUction System Pacing and Right Ventricular Synchrony (FOCUS-Right)

Evaluation and Treatment of Oral Soft Tissue Diseases

A Study of Post COVID-19 Mechanisms for Chronic Lung Sequelae

A Study of the Cardiac Effects of Danicopan in Healthy Adults

Effect of Liraglutide on Heart Frequency in Healthy Volunteers

A Study of the Cardiac Effects of ALXN1840 in Healthy Adults

Lenalidomide, Ibrutinib, and Rituximab in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma That Is Metastatic or Cannot Be Removed by Surgery

Romidepsin, CC-486 (5-azacitidine), Dexamethasone, and Lenalidomide (RAdR) for Relapsed/Refractory T-cell Malignancies